A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects-Reference-Cited by-同舟云学术

A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects

Published:2022-07-02 Issue:9 Volume:11 Page:1028-1035
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Zhou Ruirui¹²,Chen Qian¹²,Hou Sheng³,Guo Huaizu³,Li Jing⁴,Qian Weizhu⁴,Wang Hao⁴,Ou Lun⁵,Chen XiaoFei¹²,Jiang Fan¹²,Jia Jingying¹²

Affiliation:

1. Central Laboratory Shanghai Xuhui Central Hospital/Zhongshan‐Xuhui Hospital Fudan University Shanghai China

2. Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs Shanghai China

3. Shanghai Zhangjiang Biotechnology Co., Ltd. Shanghai China

4. Taizhou Mabtech Pharmaceuticals Co., Ltd. Shanghai China

5. United‐Power Pharma Tech Co., Ltd. Shanghai China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1135

Reference17 articles.

1. Rheumatoid arthritis

2. Pathophysiology of rheumatoid arthritis

3. Anti-TNF therapy: past, present and future

4. TNFα blockade in human diseases: An overview of efficacy and safety

5. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A rare case report: Myopathy related to the interaction between azathioprine and infliximab in the treatment of ulcerative colitis and ankylosing spondylitis;Clinical Case Reports;2024-05-24

2. Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis;Advances in Therapy;2023-01-06